Exicure, Inc. (XCUR) - Q3 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2024. Exicure, Inc., historically an early-stage biotechnology company, suspended all research and development activities in September 2022. The company is currently focused on exploring strategic alternatives to maximize stockholder value and has sold its historical biotechnology intellectual property and assets in September 2024. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $500,000 | $0 |
| Net Loss | $(1,091,000) | $(5,256,000) | $(2,520,000) | $(15,427,000) |
| Operating Expenses | $2,572,000 | $3,317,000 | $5,143,000 | $13,498,000 |
| Cash and Equivalents (End of Period) | $343,000 | $816,000 | $343,000 | $816,000 |
| Total Liabilities | $9,086,000 | $8,549,000 | $9,086,000 | $8,549,000 |
| Stockholders' Equity | $1,545,000 | $3,031,000 | $1,545,000 | $3,031,000 |
Note: All figures in thousands except per share data. A 1-for-5 reverse stock split was effected on August 27, 2024.
Material Changes vs. Prior Period
- Revenue Generation: The company recognized $500,000 in revenue during the first nine months of 2024 from a patent license agreement, compared to zero in the prior year. Additionally, $1.5 million in other income was recognized in Q3 2024 from the sale of historical biotechnology assets.
- Expense Reduction: Operating expenses decreased significantly year-over-year. General and administrative expenses dropped 40% in Q3 and 64% YTD, primarily due to reduced operations and the elimination of R&D expenses (which were $1.4 million YTD 2023 and $0 in 2024).
- Legal Accruals: Litigation legal expenses increased to $1.138 million in Q3 2024 (from $0 in Q3 2023) due to accruals for the unsatisfied self-insured retainer related to a securities class action lawsuit.
- Debt Conversion: In September 2024, the company converted $1 million of related-party debt into common stock.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern. With only $343,000 in cash and no significant ongoing revenue, the company requires substantial additional financing in the very near term to fund operations and strategic alternatives.
- Strategic Alternatives & Financing: The company is exploring strategic transactions. In November 2024 (subsequent to the period end), the company executed agreements to sell shares to HiTron Systems Inc. for $1.3 million (expected to close soon) and a potential $8.7 million investment subject to stockholder approval.
- Nasdaq Compliance: The company is not in compliance with Nasdaq's minimum stockholders' equity requirement ($2.5 million) as of September 30, 2024. It has received a delisting determination and is currently under an extension granted by the Nasdaq Hearings Panel until November 14, 2024, to demonstrate compliance.
- Legal Proceedings: A securities class action lawsuit settlement has received preliminary approval. The company has accrued approximately $1.14 million for the unsatisfied portion of its self-insured retainer. Negotiations with insurers are ongoing to reduce this amount.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including the precision of management's review of the Statement of Operations and the accounting treatment of non-routine activities.
Investor Verification Checklist
- Liquidity Runway: Verify the closing status of the $1.3 million HiTron investment and the likelihood of stockholder approval for the additional $8.7 million investment.
- Nasdaq Status: Monitor the outcome of the Nasdaq Hearings Panel review regarding the extension and compliance with stockholders' equity requirements by the November 14, 2024 deadline.
- Legal Settlement: Track the final settlement amount with insurers regarding the securities class action self-insured retainer to assess potential gains or further liabilities.
- Asset Sale Proceeds: Confirm the receipt of the remaining $800,000 from the September 2024 asset purchase agreement.
- Internal Control Remediation: Review the company's progress in remediating the identified material weaknesses in financial reporting controls.